Almirall, S.A.: Almirall: Lebrikizumab Combined with Topical

- Skin clearance and itch, key signs and symptoms of atopic dermatitis, were significantly improved with lebrikizumab treatment in combination with TCS BARCELONA, Spain, April 11, 2022

Related Keywords

Germany , New York , United States , Spain , Barcelona , Comunidad Autonoma De Cataluna , Spanish , Andreas Pinter , Eli Lilly , Karl Ziegelbauer , Clinical Research , Drug Administration , University Hospital In Frankfurt Main Germany , Spanish Stock Exchange , Annual Revolutionizing Atopic Dermatitis , University Hospital , Lotus Mallbris , Eczema Area , Severity Index , Investigator Global Assessment , Pruritus Numeric Rating Scale , Dermatology Life Quality , Fast Track , Noble Purpose , Inflammatory Skin Disease Summit , Cutaneous Medicine , Almirall , Lebrikizumab , Combined , Ropical , Corticosteroids , Howed , Significant , Improvements , Disease , Severity , Topic , Dermatitis ,